A New Synthetic Peptide with In vitro Antibacterial Potential Against Escherichia coli O157:H7 and Methicillin-Resistant Staphylococcus aureus (MRSA).

In this work, we performed the rational design of a cationic antimicrobial peptide, GIBIMPY4, using the software DEPRAMPs developed at the GIBIM research group. GIBIMPY4 has a length of 17 amino acids, it is amphipathic, its structure is α-helix and it has a net charge of (+5). Solid-phase peptide synthesis was performed using the Fmoc strategy in acid medium. The primary structure was confirmed by MALDI-TOF mass spectrometry. The antimicrobial activity of the peptide was evaluated by broth microdilution method by measuring optical density in 96-well microplates. The minimal inhibitory concentration of GIBIMPY4 to kill 50 % of the bacterial cells (MIC50) was 6.20 ± 0.02 µM for MRSA and 4.55 ± 0.02 µM for E. coli O157:H7, while also reporting a bacteriostatic effect for the later. GIBIMPY4 activity was sensitive to salt concentration in E. coli but insignificant effect in its activity against MRSA. The peptide seems to be a broad-spectrum antimicrobial agent based on the results against Gram-positive and Gram-negative bacteria and was specific for bacterial cells E. coli O157:H7 with index of specificity equal to 9.01 in vitro assays.

Parametric sensibility study of the sinoatrial node math model.

The results of the parametric sensibility study to the sinoatrial node math model was presented. The model was proposed by H. Zhang, A. V. Holden and M.R. Boyett. The sensitivity analysis indicates that the sodium and potassium ionic concentrations need to be controlled in order to maintain the normal behavior of the node. The calcium concentrations changes simulated don't produce significant effects over the operation of the node. One response surface model was developed as a simplification of original model. The diastolic depolarization rate was redefined in order to allow its measure in potential waves for peripheral node cells.

RGSZ1 and Ret RGS: two of several splice variants from the gene RGS20.

RGSZ1 and Ret RGS, members of the regulator of G-protein signaling (RGS) family, are GTPase-activating proteins (GAPs) with high selectivity for G alpha(z). We show here that RGSZ1 and Ret RGSZ1 are products of two of several splice variants of one gene, RGS20. RGS20 spans approximately 107 kb and contains at least seven exons. Five exons account for RGSZ1, including a single exon distinct to RGSZ1 that encodes a newly identified amino-terminal region. The previously described open reading frame (ORF) and 3' untranslated region are encoded by four downstream exons that also encode about half of Ret RGS. The 5' end of the RGSZ1 ORF contains several in-frame ATG codons (3-5 depending on the species), and multiple translational start sites may help explain the molecular weight heterogeneity of purified bovine brain RGSZ. Ret RGS replaces the 24 N-terminal amino acid residues of RGSZ1 with a large, N-terminal region that initially distinguished the bovine Ret RGS from human and mouse RGSZ1. This N-terminal domain is encoded by two distinct 5' exons that are variably combined with the four downstream exons shared with RGSZ1 to produce at least six mRNAs. They encode proteins with N termini that vary in size, hydrophobicity, and the presence of a cysteine string. At least two mRNAs that include the exon that encodes the N-terminal region unique to RGSZ1 were found in brain and a few other tissues, but not retina. RGS20 thus can account for multiple G(z)-selective GAPs in different tissues.

Regulators of G-protein signaling in receptor complexes.

G protein signaling pathways regulate heart development and adult cardiac function. G protein activity is controlled by the interplay between receptor-catalyzed activation and the inhibitory regulators of G protein signaling (RGS) proteins. Most RGS proteins are GTPase accelerating proteins (GAPs) for Gi and Gq class G protein alpha subunits, and thereby terminate signaling. However, RGS proteins also provide scaffolding properties to help assemble or maintain signaling complexes. Thus, RGS proteins are kinetic regulators that may sharpen both signal activation and termination. The five subfamilies of mammalian RGS proteins contain a characteristic RGS domain and distinct flanking domains that convey lipid and/or protein interactions within receptor complexes. The RGS domain provides GAP activity and additional interactions with the receptor complex. Distantly related RGS-like (RGL) proteins provide other regulatory and effector functions in G protein signaling pathways. RGS and RGL proteins provide exciting new therapeutic targets to combat cardiovascular diseases.